gemcitabine,cisplatin,carboplatin,enfortumab,pembrolizumab
astellas,seagen,merck
['urothelial', 'enfortumab', 'pembro', 'ev302', ' vedo', 'ev-103']
 presents #ev-103 dose escalation/cohort a: long-term outcome of enfortumab vedotin + pembrolizumab in 1l cis-ineligible metastatic #urothelialcarcinoma with 4 years of follow-up shows manageable toxicity and consistently positive outcomes we await ev302 @ asco #asco23 
Medical Oncologist, Investigator, Chief, #BladderCancer Section, #GenitourinaryTumors, NCI, NIH #RareTumors #PatientAdvocate, Latina. Views are my own